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Abstract
Background: Few studies explore stroke survivor views and motivations towards stem 
cell therapy (SCT). This qualitative study explores the views and motivations of both 
stroke survivors and their partners/carers towards a proposed 2- arm Phase III 
Randomised Controlled Trial (RCT) comparing intracerebral insertion of stem cells 
with placebo neurosurgery in stroke survivors with disability.
Objective: To explore views and motivations towards a proposed 2- arm stem cell trial 
and identify factors that may impede and enhance participation.
Design: This study adopts a naturalistic design to explore the complexity of this field, 
employing a participatory action- research approach comprising a specialized 
Conversation (World) Café form of focus group. Data were collected via 5 Conversation 
Cafés with stroke survivors (age 40- 75) and partners/carers between June and 
October 2016. Of 66 participants, 53 (31 male, 22 female) were stroke survivors and 
13 (6 female, 7 male) were partners/carers. Qualitative data were analysed using a 
thematic approach.
Discussion and Conclusion: Stroke survivor views and motivations reflect anticipation 
of the personal and future benefits of regenerative medicine. Partners/carers sought 
to balance the value of stroke survivor hope with carrying the weight of hope as carer, 
a conflict burden adding to known caregiver burden. All participants expressed the 
need for during and post- trial psychological support. This study provides a rare oppor-
tunity to explore the prospective views and motivations of stroke survivors and their 
partners/carers towards a proposed Phase III 2- arm RCT. This adds weight to qualita-
tive evidence exploring capacity, consent, decision making, perceptions of treatment 
risk and supports required for clinical trial participation.
K E Y W O R D S
caregiver burden, consent, regenerative medicine, treatment decision-making
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1  | INTRODUCTION
Stroke is the third leading cause of complex disability: over half of 
1.2 million stroke survivors live with disability caused by damage to 
brain tissue/cells as a result of blockage or haemorrhage of the blood 
supply.1 Stroke can impair a range of cognitive and physical functions 
and significantly impact on individuals’ and carers’ quality of life.
Recent scientific research focuses on investigating the therapeutic 
value of stem cells to replace lost or damaged cells from stroke. Early 
stage phases I and II clinical trials have demonstrated the safety of in-
jecting intracerebral stem cells.2,3 The proposed Phase III Randomised 
Controlled Trial (RCT) aims to assess the safety, tolerability and efficacy 
of intracerebral stem cells in patients with disability following an isch-
aemic stroke. Participants will be randomized (2:1) to active or placebo 
neurosurgery. Stereotaxic methods will be used to inject the cells via 
a cannula into the damaged hemisphere using local or general anaes-
thetic and analgesia. For patients allocated to receive placebo, only the 
outer table will be removed and the dura will not be breached during 
the procedure. Similar placebo- controlled surgical trials have been con-
ducted in other fields (in Parkinson’s disease, eg4,5), but the proposed 
stem cell therapy RCT is novel in the field of stroke and has the poten-
tial to raise questions from participants and the medical community.
Many trials struggle to recruit and retain target patient numbers, 
and only about 50% reach their recruitment target.6,7 This jeopardizes 
the trial’s internal and external validity, potentially delaying the devel-
opment of more effective treatments.8,9 Recruitment is reported to 
be particularly difficult for trials involving randomization and placebo 
arms10-12 and is predicted to be challenging for trials involving stem 
cells due to anticipated ethical and moral uncertainties about risk- 
benefits.13 Among the factors influencing trial recruitment rates, pa-
tients’ beliefs and preferences have been identified as key barriers to 
participation.14 This study provides further evidence highlighting the 
views and motivations of the target patient group and identifies fac-
tors that may impede and motivate patient participation.15
Ethical principles governing clinical trials require that patients 
provide informed consent following a voluntary and informed deci-
sion about taking part or not.16 An informed decision requires that 
individuals consider information about all available options and their 
consequences, evaluate this information in accordance with their 
own values, preferences and circumstances and make a deliberate 
choice based on trade- offs between these evaluations.17 In the con-
text of stem cell trials for stroke, this process is also likely to be 
shared among patients, carers and their health professionals, each 
bringing their own values and preferences.18 Factors such as con-
trasting views and motivations, expectations of curative benefits, 
and the context in which trial recruitment takes place may render 
the decision- making process susceptible to biases.19,20 Recruitment 
procedures therefore must ensure that patients and families are 
enabled to make an informed decision. Study sponsors must bal-
ance the ethical aspects of the Phase III trial protocol and potential 
therapeutic misconceptions against strategies to optimize trial re-
cruitment. Standard processes put in place to enable informed con-
sent have been recently criticized as suboptimal for not meeting the 
needs of patients in terms of making an informed decision, calling 
for alternative approaches to be developed.20-23
Given the dual challenge of maximizing trial recruitment while re-
specting and supporting individuals’ informed decision making, this 
research was sponsored to further understand the views and motiva-
tions of people affected by stroke and their partners/carers towards 
the proposed Phase III two- arm trial. While current evidence13,24 high-
lights some positive motivations towards stem cell therapy, this study 
extends understanding by highlighting stroke survivor and partner/
carer views as a two- way involvement process, revealing key imped-
iments that require targeted support to enhance participation in the 
proposed Phase III trial.
2  | METHODS
2.1 | Design
Qualitative methods are well suited for investigating concepts such as 
views and motivations within the patient community to help explain 
the processes at work in the uptake of new interventions and decision 
making around trial participation.25
This study adopts a naturalistic design26 to explore complexity in 
this field, adapting from a participatory action- research approach com-
prising a specialized World (Conversation) Café form of focus group. 
The Café approach creates a relaxed, informal and conversational 
environment, facilitating constructive engagement around complex 
issues and critical questions. This is an effective format for hosting 
interactive and large group dialogue. Each Conversation Café event 
begins with an introduction by the lead host (first author) to set the 
context and put participants at ease. Each event comprises up to five 
tables (4- 5 participants) and one host (researcher) and consists of a 
series of conversation topic rounds lasting up to 20 minutes (Table 1). 
The role of each table host is to provide structure and orienteering 
as the café process unfolds, encouraging conversation without tak-
ing over. A final plenary session, delivered by the lead host, draws to-
gether key agreed themes, inviting individuals to share further insights 
from their larger group conversations.27
2.2 | Population, sampling and participant 
recruitment
Potential participants were identified from UK stroke community 
support groups. These groups can be advantageous to stroke sur-
vivors and their partners/carers as they often combine social func-
tion with physical rehabilitation therapy. While each individual stroke 
TABLE  1 Conversation Café rounds
Round 1 Proposed trial: all views
Round 2 Information needs
Round 3 Trial protocol: skewed randomization and placebo 
group
Round 4 0- 12 months post- stroke
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experience may be unique, there are common themes within stroke 
narratives and many use the support group to share their strategies 
for overcoming challenges.28
Sampling decisions were conceptually driven.29 At the centre of 
this framework were the experiences of stroke survivors and their 
partners/carers. Purposive predetermined sampling procedures were 
used to identify community groups based on relevance to the research 
topic and to ensure a broad range of views and motivations.30 Sample 
size was guided by early analyses taking place alongside continuing 
data collection, until no new themes emerged from the data and data 
saturation could be confirmed.31
2.3 | Data collection
Data were collected via five Conversation Café events held June and 
October 2016. Criteria for participation were stroke survivors aged 
40- 75 who had experienced stroke within the previous 36 months and 
partners/carers. Of the total 66 participants, 53 (31 male and 22 female) 
were stroke survivors; four of whom had experienced recent stroke 
within 12 months and 13 (six female, seven male) were carers. While this 
research sample is not representative of the diversity of the general pop-
ulation, Café locale represent a mixed demographic from across the UK.
2.4 | Materials
Information sheets, consent forms and topic guides were provided 
prior to the Conversation Café event at scheduled pre- Café infor-
mation sessions (led by first author) and during Café registration if 
required. Participants were only recruited to the study if they could 
give informed consent. This meant that participants had a clear un-
derstanding of what involvement in this research meant and what was 
expected of them. All participants were advised that participation was 
voluntary and did not prejudice future treatment choices. If individuals 
were unable to sign consent forms, then verbal consent was accepted.
Conversation Café topic guides with probes (Table 2) were in-
formed by evidence and literature on experience and attitude towards 
placebo- controlled trial31-34; the effect of randomization as a predictor 
of volunteering35,36; therapeutic misconception,37 attitudes to stem 
cell use and donation.38,39
Each table, with refreshments provided by the research group, 
held a focused group conversation using the study topic guide.40 All 
Conversation Café events were audio- recorded and transcribed ver-
batim. Participants were also provided with Post- Its, pens/pencils and 
writable tablecloths to record any notes or comments. This was also 
employed as an aid for those with speech difficulties or reluctant to 
voice opinion within a group setting.
2.5 | Ethical considerations
All Conversation Café hosts were skilled qualitative researchers, expe-
rienced conducting research with vulnerable groups and around sensi-
tive issues. This study received ethical approval from the University 
Research Ethics Committee (version 2: 07- 04- 16).
2.6 | Analysis
Data were analysed using thematic analysis41 to identify, interpret and 
report patterns and themes within the data. An initial coding framework 
(Table 3) was developed with data from 2 Conversation Café’s, chosen 
to provide a fair representation of the range of participants. A constant 
comparative process comparing the relative frequencies of theme and 
topic enabled initial coding of data. Box 1 provides example of coded 
data extracts alongside early interpretive processes. Two members of 
TABLE  2 Conversation Café topic guide
What do you think about the proposed clinical trial?
a. What are your main concerns about trials like this?
How would you feel if your partner/relative was taking part?
What kind of information would you need to be able to make a 
decision about taking part in a trial like this?
Do you think any of the following would affect someone’s decision to 
take part?
a. More likely to receive the actual treatment than be part of the 
control group (ie skewed participation)
b. Or if part of control group be offered the same treatment (if 
successful) at a later date/12 months?
c. Would you prefer to be asked what preference you have? That is, 
prefer to receive the specific treatment; prefer not to receive 
treatment; or are neutral?
Thinking back to the first 12 months after diagnosis, would your 
opinion have been different in any way?
Is there anything else that would affect your decision to take part?
If you decided to take part, what would be your reasons?
If you decided not to take part, what would be your reasons?
TABLE  3  Initial coding framework
Information needs
Placebo and skewed randomization
Anaesthetic risk
Physical capacity
Depression (known and unknown)
Quality of life
Carers support needs
Carer risk and loss
Lay knowledge and assumptions
Altruistic motivation
Scientific progress
Lay knowledge/therapeutic misconceptions
Psychological effects/concerns
Patient vulnerability
Being normal
Comorbidities
Hope(full)
Hope(less)
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the research team undertook this procedure simultaneously. Similarities 
and consistencies ensured reliability and trustworthiness of the analyti-
cal process. Table 4 provides example of the movement from the initial 
coding framework to the next stage mid- ordering of codes. The codes 
illustrated provide example of diversity and pattern within the data. 
Those too diverse or lacking in depth were discarded. The next analytic 
stage focused on searching for themes and combining different (and 
sometimes similar) codes to represent aspects within the data. Visual 
thematic mapping enabled the consideration of links and relationships 
to support the interpretive process. Figure 1 illustrates the movement 
between the mid- stage ordering of codes to first organizing themes. 
This reflects a process of clustering, collapsing and combining codes 
that shared unifying features so that they reflected and described 
meaningful patterns. For example, we noticed code clustering and 
overlap around risk, motivation and caring. Examined in detail, we iden-
tified the codes reflected positive and negative talking and often con-
flicting views and motivations between patients and partners/carers. 
Figure 2: Global Schematic represents a visual thematic map illustrating 
the final process of defining, refining and naming themes to capture the 
most important and relevant elements of the data. Box 2 clearly states 
what is unique and specific about each theme.
3  | RESULTS
The themes identified below represent themes identified, albeit some 
elements may overlap. This does, however, represent relationships be-
tween views and motivations as opposed to suggesting all concepts 
Box 1 Example coded data
Data extract Coded for
So you would support him in this type of trial? (Café Table Host)
Yes but like I said, he needs hope but maybe I don’t [pause]. He would be full of it. You know 
what he’s like? He’d convince himself every bit of movement was some change because of 
it. And maybe it might be but maybe not? [Pause] It’s so difficult [E: C50)
Would anything help you? (Café Table Host)
I don’t really know. Someone to talk to but I don’t know really? I don’t have much time. Not 
sure if I’m into that really! I’m not sure if talking about one bit would be like taking my 
finger out of the dam [pause] … [laughing] … If I say no it feels like I’m condemning him. 
(E: C50)
Carer risk, loss and support needs. Managing carer 
burden
Managing hope (patient and carer perspectives)
Patient vulnerability enhanced by anticipation
Therapeutic misconceptions affected by lay 
assumptions
… We need to do this but I’d worry like? Worry for her in case anything went wrong. I do 
most of the care and look after the kids. So does our parents … I don’t know if they’d 
understand; cope with more worry. I wouldn’t want to give them any hope? They’ve been 
so upset. But I know she’d want this, wouldn’t you [looking at E: P2) P2 nodding] [pause] 
But [pause] it would be hard to go through this and see it not work. (E: C2)
Risk
Carers worry about coping and burden
Carer and patient vulnerability
Feeling conflicted: two- way decision making
Hope(full)
So, Superman was right wasn’t he? [group nodding strongly in agreement] Who’d have 
thought?” Shame he couldn’t last longer. Tragic. They could’ve had him up and walking by 
now, eh? [group nodding in agreement] (E: P5)
Table Host: I’m not sure any improvement would be as dramatic as that? Does that make a 
difference?
I know you don’t want to give us too much hope but I think there’s a lot going on isn’t there? 
Ah mean, it hasn’t been that long since Superman. Now it’s Michael Schumacher, isn’t it? 
Next thing we’ll see is him walking, y’know? That’s why there’s a news blackout on it. (E: 
P5) [group nodding strongly in agreement].
Table Host: I’m not so sure. Do you really think so?
Mark my words [emphasis] and watch for the papers! [E: P5]
Therapeutic misconceptions lay assumptions and 
media effects
Too much hope(full)?
Risk- averse?
Patient vulnerability linked to assumptions
Anticipation and the superman effect
TABLE  4 Mid- ordering: 7 codes with illustrative data extracts
Motivations affected by lay 
assumptions Trial information needs Risky decision making Early decision making post- stroke Post- trial experiences and supports The effects of hope Carers involvement and conflict
… And would it bring things 
back? Obviously the things 
I’ve forgotten, Y’know?
So superman was right wasn’t 
he? … They could’ve had him 
up and walking by now
… you’d want to know the surgeon was professional 
… and that they knew what they were doing … and 
if they knew that I’d lost my speech …
I’d be a bit worried about stuff. Like do they screen 
them? Make sure they’re safe?
I want to know I have a fair chance of getting 
treatment …
So you’re saying then that I won’t know whether 
I’ve been given them … and I might get the change 
to have them later? So that would be two 
anesthetics then?
They wouldn’t allow me to fly for a year because 
they were scared of a bleed… so going back to 
3- 11 months? It’s part of the medical intervention 
… you must take it easy … There’s a bit of 
confusion there?
… But if I’d been asked to participate in  
that first few months, I would’ve said  
yes but I might’ve been confused a  
bit … It took me a whole for the fog to  
clear …
If you’d gone to ask her within the first  
year … it’s cognitive … you wouldn’t  
have got a rational answer …
What I’m thinking is you can be set in your ways after stroke … And if you 
find out it’s placebo like … you might get really down- hearted.
What happens to everyone after the trail has ended? Will anyone check 
how we’re doing?
You’d have to make sure people coming out are getting extra help …
… It might give hope … Y’know false hope to some people … 
how would they cope with that?
I think they would need an awful lot of support to come to 
terms with that afterwards?
… Yes but like I said he needs hope but maybe I don’t?
Anything … any change [emphasis]. Some hope [emphasis] 
… would be worth it
… a lot of changes appear cognitively, 
memory …
… so I do think as well like it needs the 
carers consent?
It’s often harder for the partner [pause] …
watching on, from the outside, for their 
partner and in any situation like that looking 
on,
She was still in shock. Couldn’t hold the 
kids? She’d have jumped at it …
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should be understood in isolation. The coding key used reflects Café (A- 
E), P or C (patient or partner/carer) and numerical participant identifier.
3.1 | Anticipation and regenerative medicine: 
Superman was right, wasn’t he?
Anticipation of possible therapeutic benefits enhanced stroke survi-
vor’s positive motivation towards the proposed trial. The suddenness of 
stroke can leave the individual with a sense of discontinuity42 combined 
with feelings of loss, fear and hopelessness. Views and motivations to-
wards participation connected to feelings of hopelessness and the lack 
of extended post- stroke rehabilitation services and support to aid a 
hoped- for “return to normal” (A: P6). Many participants reported feeling 
left to their own fate by the health service after only short periods of re-
habilitation. This, combined with pervading disability and reduced qual-
ity of life, informed some strong motivation towards the proposed trial:
TABLE  4 Mid- ordering: 7 codes with illustrative data extracts
Motivations affected by lay 
assumptions Trial information needs Risky decision making Early decision making post- stroke Post- trial experiences and supports The effects of hope Carers involvement and conflict
… And would it bring things 
back? Obviously the things 
I’ve forgotten, Y’know?
So superman was right wasn’t 
he? … They could’ve had him 
up and walking by now
… you’d want to know the surgeon was professional 
… and that they knew what they were doing … and 
if they knew that I’d lost my speech …
I’d be a bit worried about stuff. Like do they screen 
them? Make sure they’re safe?
I want to know I have a fair chance of getting 
treatment …
So you’re saying then that I won’t know whether 
I’ve been given them … and I might get the change 
to have them later? So that would be two 
anesthetics then?
They wouldn’t allow me to fly for a year because 
they were scared of a bleed… so going back to 
3- 11 months? It’s part of the medical intervention 
… you must take it easy … There’s a bit of 
confusion there?
… But if I’d been asked to participate in  
that first few months, I would’ve said  
yes but I might’ve been confused a  
bit … It took me a whole for the fog to  
clear …
If you’d gone to ask her within the first  
year … it’s cognitive … you wouldn’t  
have got a rational answer …
What I’m thinking is you can be set in your ways after stroke … And if you 
find out it’s placebo like … you might get really down- hearted.
What happens to everyone after the trail has ended? Will anyone check 
how we’re doing?
You’d have to make sure people coming out are getting extra help …
… It might give hope … Y’know false hope to some people … 
how would they cope with that?
I think they would need an awful lot of support to come to 
terms with that afterwards?
… Yes but like I said he needs hope but maybe I don’t?
Anything … any change [emphasis]. Some hope [emphasis] 
… would be worth it
… a lot of changes appear cognitively, 
memory …
… so I do think as well like it needs the 
carers consent?
It’s often harder for the partner [pause] …
watching on, from the outside, for their 
partner and in any situation like that looking 
on,
She was still in shock. Couldn’t hold the 
kids? She’d have jumped at it …
F IGURE  1 First organizing themes: 5 main themes
Positive 
talk
Negative 
talk
Information 
needs
Awareness 
of stem cell 
trials
Lay 
assumptions
Hope(full)
Doing 
something, 
action
Quality of life
Physical 
limitations
Depression
Risk 
(carers)
Dealing with 
effects of 
stroke
Risk 
(patient
Hope
(less)
Being normal
Carer tensions 
Impacts
Therapeutic 
misconceptions
Comorbidities
Progress
Care burden
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Anything [pause] any change [emphasis] [pause] would be 
worth it.
(E: P2, severe aphasia)
C: P1 had experienced ischaemic stroke after anaesthesia complica-
tion during a routine and scheduled operation:
… I thought I was indestructible [pause] indestructi-
ble [emphasis] but I would do it if there was a chance. 
Anything [emphasis] is better than this!
(C: P1, aphasia)
As an emerging science, regenerative medicine is surrounded by 
many myths and misperceptions, evoking enthusiasm and passionate 
debate alongside heightened health expectations.43,44 Stroke survivor 
views and motivations reflect less the measured risk- benefit evaluation 
and more strong anticipation of personal and future benefit combined 
with scientific breakthrough:
It’s amazing what a stem cell can do to repair areas! Maybe 
in the future it can turn a face back 30 years, which would 
be good. I’ll go for that!
(C: P1)
I know it might not be for me, for me ever … but to think 
that people are doing something [pause] that feels good! 
[Excitement] I’d like to replace Jessica Ennis at the next 
Olympics! [Group laughing] (E: P3) The partner of P3 
Box 2 Definitions and labels
Anticipation: Superman was right, wasn’t he?
Outlines how stem cell therapy is a fast- developing area of research and treatment, driven by better understanding of potential therapeutic 
opportunities and promising early phase clinical trials. Participant narratives are influenced by strong media coverage exalting the recovery 
of people disabled by stroke often enhancing known therapeutic misconception. Participants—particularly stroke survivors—praised the 
potential assumed benefits via stem cell therapy—and in contrast to the measured information given to them. Generally, positive media 
reporting also appeared to influence the general acceptability of participation in stem cell trials. While some participants requested further 
detail, most expressed a lack of concern. In general, participants—stroke survivors in particular—held strongly positive optimism towards 
stem cells which may require specific and targeted support.
Capacity and decision making: Making a snap decision
Outlines how participants identified key issues in relation to capacity and vulnerability during the proposed trial decision making and treat-
ment period. Participants highlighted the difficulties of known cognitive, orientation and functional impairments post- stroke and expressed 
concern around capacity for informed consent during the time- period proposed. Many also highlighted the unknown difficulties that may 
emerge during and beyond participation.
Care conflict: Balancing hope
Focuses on developing understanding of known caregiver burden54,55 and in relation to participation in clinical trials. This third theme also 
represents elements of the above 1st and 2nd final themes. Negative and positive discussions around the proposed trial reflected conflicting 
motivations and competing pressures. Partners and carers narratives illustrate a two- way involvement in trial participation decision making, 
constantly weighing up perceived risks and benefits and assuming some responsibility for managing motivations. While all partners and carers 
provided support, the strong notes of caution and concern constitute important additional elements in our understanding of caregiver burden, 
trial decision making and the extended supportive interventions required during trial recruitment, participation and post- participation.
F IGURE  2 Global Schematic: 3 main 
themes
Anticipation Care 
conflict
Capacity 
Progress
Hope
Action
physical Distress
Vulnerability Psychological 
distress
Risk
Conflict
Burden
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noted this reaction: I haven’t seen you light up like this for 
a while!
(E: C3)
Many stroke survivors overestimated possible benefits. This con-
tinued through all discussions, despite Table Host attempts to temper 
assumptions around therapeutic benefit. There was little evidence 
that the presentation of a more measured view of possible physical 
improvement had any impact on views and motivations towards this 
type of trial:
My dementia was caused by my stroke. Would this treat-
ment sort my dementia as well? And would it bring things 
back? Obviously, the things I’ve forgotten, y’know?
(A: P2)
So, Superman was right wasn’t he? [group nodding strongly 
in agreement] Who’d have thought?” Shame he couldn’t 
last longer. Tragic. They could’ve had him up and walking 
by now, eh? [group nodding in agreement]
(E: P5)
Table Host: I’m not sure any improvement would be 
as dramatic as that? Does that make a difference? 
I know you don’t want to give us too much hope but I think 
there’s a lot going on isn’t there? Ah mean, it hasn’t been 
that long since Superman. Now it’s Michael Schumacher, 
isn’t it? Next thing we’ll see is him walking, y’know? That’s 
why there’s a news blackout on it.
(E: P5) [group nodding strongly in agreement]
Table Host: I’m not so sure. Do you really think so? 
Mark my words [emphasis] and watch for the papers!
[E: P5]
Highly anticipative discussion can be contextualized against the sud-
den impact of stroke and often long- term effects. Views and motivations 
were conditionally influenced by strong assumptions around therapeu-
tic benefit and may extend beyond motivations towards the collective 
good. While these findings resonate with known work highlighting con-
ditional altruistic motivation43,44 towards trial participation, in this study, 
participation- benefit- risk reasoning was measured against at times unre-
alistic assumptions around treatment outcomes.
3.2 | Capacity and decision making: A snap decision?
Participants were invited to reflect back to the 3- to 11- month pe-
riod post- stroke during conversation. All groups raised concerns over 
the value of physical therapy and rehabilitation services. For many, 
these services had been restricted to 6 weeks post- stroke. Many 
described a sense of abandonment by mainstream health services 
when this ended. The proposed trial offers assignation to a physical 
therapy programme pre- randomization, to be self- delivered after an 
initial training programme. Physical therapy would be continued for 
12 weeks post- surgery.
Concern around physical capacity affected positive motivation 
towards the proposed trial. Participants expressed some unease and 
described the incapacitating effects of stroke on cognition, orientation 
and functional capacity. Participants were advised that the proposed 
trial would include pre- trial screening and cognitive/quality of life as-
sessment (Rankin Scale). While this did enhance motivation towards 
trial participation, many participants stated the extent of impairment 
and vulnerability was only revealed retrospectively:
It’s been 18 months since, now. Y’know, I’m not crying as 
much now [laughing] But I think if I’d been asked to par-
ticipate in that first few months, I would’ve said yes but I 
might’ve been confused a bit … It took me a while for the 
fog to clear … I only knew I was in a fog when it was gone.
(E: P9)
Just to add to what we were saying—I know they’ll as-
sess you and see whether they think you could take part 
and you’re ok an’ that [pause] But not many others really 
noticed that [looking at partner] I just seemed a bit quiet 
didn’t I? [partner nodded] [pause] but I didn’t know it was 
more than that but I don’t know whether they could pick 
that up, y’know?
(E: P5)
Many participants viewed psychological support both during and 
beyond the trial as a critical support mechanism. This was because trial 
participation would combine with acute- stage stroke recovery at a time 
when cognitive and functional improvement may be slow.
The invisible consequences of stroke often include uncontrolled 
emotion compounded by short- term memory loss and problems with 
comprehension. Participation and decision must depend on partic-
ipants understanding the aims, treatment, protocol, possible risks, 
benefits and rights to withdraw from trials.45 Reflecting back, some 
participants considered the immediate period post- stroke as a time of 
“feeling vulnerable” (C: P3). Making decisions during this period was 
considered problematic:
It was a tough time. Can imagine it would have been diffi-
cult to think about it? I dunno [pause] maybe some would 
be [pause] vulnerable?
(E: P5)
For some, this increased the likelihood they would make a “snap” de-
cision. Acute illness can impair understanding—and particularly concepts 
of proportionality and risk. Even when tests of cognitive function appear 
normal, there may be other unknown influencing factors and this reflects 
some concerns:
I probably would have grasped at straws, I don’t know. I 
[pause] desperation? Yes, I was massively depressed and 
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I would have been glad of perhaps anything that would 
have perhaps helped.
(E: P6)
… Actually, one of the things about the trial I worry about 
already is Group B [placebo]. They’re going to face the pos-
sibility that they are in the wrong group. That needs a lot, 
I mean, the depression and the anti- climax when they find 
out they didn’t have anything [pause] the expectation of 
that I think would be devastating [pause] And then Group 
A. You’d need help for disappointment you know if it’s not 
going to work [pause] helping you if you’re thinking this is a 
cure type of thing you know?
(A: C1)
Given potential difficulties assimilating trial information during the 
acute post- stroke period, participant transition through and beyond the 
trial was considering as troubling by participants:
Some people the depression hasn’t come on for … 12 
month… people think that when they’ve left [hospital] and 
come home, when they’ve got over that threshold of home 
there’s fairy dust … kind of magic … that makes everything 
alright but it doesn’t. There’s a whole different set of prob-
lems; the depression can kick in, so this could be 6- 12 months 
down the line and they’ve already got involved in the research 
thinking it’s the hope of all hope and then they’re not getting 
miraculous results that they would expect regardless of what 
expectations people have said, that can make it worse I think.
(C: C1)
Participants described the trajectory towards depression as a slow 
one—a real fear for some and a reality for many. The difficulty negoti-
ating this trajectory combined with trial participation while hoping for 
recovery was a strong concern. All participants identified the need for 
during and post- trial psychological support.
3.3 | Care conflict: Balancing hope
Caregiver burden is recognized as a significant health- care concern46 
and elevated for an indefinite period following stroke.47 Carers play 
an important role in post- stroke rehabilitation, may enable a return 
to live at home or in the community and potentially positively impact 
on health outcomes. In this study, partner/carer views towards the 
proposed trial were qualified by key fears and concerns. Many first 
described feeling inadequately prepared for their unexpected role as 
carer. Although generally supportive of stem cell research and the 
proposed trial, partners/carers raised concerns around the potential 
risks of participating in this type of trial and the impact of regret if the 
trial did not bring individual benefit or caused harm:
I think if someone has had a stroke they really need to un-
derstand what has happened. And the person making the 
decision really needs to understand, and for the family too 
and consent and things [pause] My main concern would 
be that the operation could go wrong, I mean because 
every operation has a risk, I’d worry that it would make 
him worse.
(B: C2)
I’d be concerned about the fear of how it would affect you? 
[Looking at partner, C: P1]. How disappointed you would 
be if it didn’t work as [C: P1] has depression which could 
get worse [pause] coping with the depression and the anti- 
climax when they find out they didn’t have anything?
[C: C1]
The prevalence of neurological impairment, depression and anxiety 
is known effects continuing up to 5 years after an incidence of stroke.48 
Partner/carer views about the proposed trial also highlighted psycholog-
ical concerns in relation to the possibility of post- treatment regret, antic-
ipated to bring additional difficulties not only to stroke survivors but also 
to partners/carers. Partners/carers reported watching “from the outside” 
[D: C1] and feeling conflicted between the possible hope offered by 
stem cell therapy, regret if difficulties were experienced and guilt:
It’s often harder for the partner [pause]. Well, not harder, 
that’s a lie, but somebody that’s watching on, from the 
outside, for their partner and in any situation like that 
looking on, it’s often harder, if the person doesn’t realize 
what’s happened to them. But we’d all like to benefit. I’ll 
not say anymore [pause] I’m getting the look [from C: P1] 
C: C1 becomes emotional.
… We need to do this but I’d worry like? Worry for her in 
case anything went wrong. I do most of the care and look 
after the kids. So does our parents … I don’t know if they’d 
understand; cope with more worry. I wouldn’t want to give 
them any hope? They’ve been so upset. But I know she’d 
want this, wouldn’t you [looking at E: P2, P2 nodding] 
[pause] But [pause] it would be hard to go through this and 
see it not work.
(E: C2)
In this study, a new dimension was revealed as partners/carers felt 
conflicted as they sought to balance the value of hope for the stroke 
survivor with carrying the weight of hope felt as carer.
The carer has to go through the fact that their loved one 
who’s nearly died, who’s had a stroke, it’s a big thing 
[pause] but they’ve not died but they’re going to put them-
selves at further risk with having a hole drilled [pause] 
and they might desperately want it because they think it’s 
going to do them the world of good but the carer you know 
is on the end of that.
(E: C50)
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This conflict adds to known caregiver burden and was sometimes 
expressed as guilt for not being supportive enough:
So you would support him in this type of trial?
(Café Table Host)
Yes but like I said, he needs hope but maybe I don’t [pause]. 
He would be full of it. You know what he’s like? He’d con-
vince himself every bit of movement was some change be-
cause of it. And maybe it might be but maybe not? [Pause] 
It’s so difficult
[E: C50)
Would anything help you?
(Café Table Host)
I don’t really know. Someone to talk to but I don’t know 
really? I don’t have much time. Not sure if I’m into that 
really! I’m not sure if talking about one bit would be like 
taking my finger out of the dam [pause] … [laughing] … If I 
say no it feels like I’m condemning him.
(E: C50)
Across all groups, discussion revealed some key differences between 
stroke survivors and partners/carers. This provided further insight into 
the needs of stroke survivors and partners/carers and the support mech-
anisms that may be required to enhance participation.
4  | DISCUSSION
This study provides a rare opportunity to explore the prospective 
views and motivations of stroke survivors and their partners/carers 
towards a proposed 2- arm RCT using stem cells via placebo neurosur-
gery. Our findings add qualitative weight to recent evidence (see Ref. 
24). The following section considers the factors that further impede 
participation and suggests strategies to enhance participation.
4.1 | Conflict burden
It is important to highlight that supportive views and motivations to-
wards the trial were influenced by high expectations of personal ben-
efits, a “conditional altruism” influenced by (i) strong media reporting 
of earlier trial results and (ii) therapeutic misconception concerning 
the restorative potential of stem cells.43,49 However, partners/carers 
revealed contrasting viewpoints and motivations. Partners/carers of 
survivors with neurological disease are known to have a higher risk 
of physical, mental and emotional depletion and reduced quality of 
life.47 Our findings indicate that partner/carer views and motivations 
were influenced by different perceptions and trade- off between risk- 
benefit. We introduce the concept “conflict burden”: carers report 
conflict, guilt and increased concern in relation to assumed physical 
and psychological risks involved when faced with stroke survivor’s 
motivations towards clinical trial participation. This “conflict burden” 
was underlined via described tension between stroke survivor hope-
fulness and carers felt- conflict supporting hopefulness.
4.2 | Two- way involvement
Stroke survivors and their partners/carers discussion highlighted a 
two- way involvement in decision making. These findings remind us 
that when developing information and decision- aids, survivor views 
should be placed at the core but this should not be to the exclusion 
of the views of partners/carers. Our study adds to evidence for trial 
information to be framed in the context of patients’ and partners/
carers—interpersonal relationships and complex decision- making 
processes.22,50,51
It is worth noting that some consideration has been given to this 
issue in related fields.52-54 Alzheimer’s, as an irreversible neurological 
disease, also impairs cognition, orientation and functional capacity. 
The carer is often actively supported to be involved in decision mak-
ing. Current recommendations to support participation in clinical tri-
als position the carer as “study partner” to aid with decision making 
and consent.55 Stroke carers also experience the effects of stroke as 
sudden, unpredictable and disruptive, affording insufficient time for 
preparation in advance of complex care responsibilities. While carer 
involvement in decision making may relieve some of the difficulties 
of cognition, orientation and functional capacity, conversely, this re-
sponsibility may also cause conflict and add weight to known carer 
burden.56,57 Our data suggest interventions should be mindful of 
the complex and at times, conflicting caring and interpersonal con-
text14,18,32 when exploring ways of involving and supporting carers 
through the clinical trial decision- making process.
The timing of the proposed trial during the 3- to 11- month period 
post- stroke was a concern for all participants, particularly in relation to 
the difficulties of survivor cognition, orientation and functional capac-
ity. The acute effects of stroke may also include being prone to impul-
sive decision making and experiencing impairment balancing rewards 
with risk.58 This may combine with uncertainty, disruptive and shifting 
changes, a trajectory of post- stroke depression, either in the early or in 
late stages after stroke. During this period, stroke survivors must eval-
uate the trial and make decisions about risk- benefit. This represents 
a delicate trade- off59 and one that may be compromised during the 
acute recovery period.
Our findings highlight key concerns and add evidence to recent 
work exploring decision making and strategies to alleviate recruit-
ment difficulties.20,43,60 The conflicting effects of hope on stroke 
survivors and partners/carers are a notable concern. These effects 
may make trial participants more vulnerable and carers/partners 
more burdened.
4.3 | Enhancing participation
The findings of this study have implications for supportive care 
through clinical trial participation. Recent developments have made 
positive moves forward. Current trialists are including evaluation of 
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their recruitment strategies, a development received positively by 
Funding Councils and recommended via the UK Medical Research 
Council. Development includes the QuinTet Recruitment Intervention 
(QRI), evolved from15,60 a pioneering embedded complex recruitment 
intervention in the ProtecT trial. The Q- QAT intervention uses ini-
tial quantification of recruitment appointments to inform qualitative 
research to understand the issues and make suggestions to improve 
recruitment.
While many trials seek tools to inform and facilitate improved re-
cruitment rates, there is less emphasis on requirements for post- trial 
support. In our study, retrospective consideration revealed concerns 
around psychological support during and post- trial participation; par-
ticularly, if the nature of impairment may escape detection during pre- 
trial cognitive screening. For example, participants expressed concern 
their depression trajectory emerged during later months post- stroke, 
and the possible negative impacts from trial participation, particularly 
unblinding to placebo post- trial.
This study suggests strategies to enhance participation should 
include: consideration of consent as a two- way involvement process 
between stroke survivors and carers, best obtained as (at least) a 
two- stage process: initial consent followed by reaffirmed consent at 
interval and including appropriate time for reflection. Known and un-
known cognitive and functional impairment and concerns around ca-
pacity and vulnerability were primary concerns in this study. Following 
NICE guidelines, this may be supported via the implementation of a 
stroke- specific stepped- care model of support at key interval periods. 
The support needs of partners/carers should be given independent 
consideration. Carer strain, burden and conflict should be reassessed 
regularly. This could coincide with trial follow- up dates and be accom-
panied by direction to regularly scheduled counselling services and/or 
partner support groups.
5  | CONCLUDING REMARKS
Achieving optimal recruitment rates can be difficult, particularly in 
relation to highly invasive trials. Our findings highlight critical stroke 
survivor and partner/carer concerns. Set against the context of 
cutting- edge medicine and possible therapeutic misperception, clini-
cal trial protocol requires the inclusion of fully embedded, multiple 
time point information, advice and support processes to ensure re-
quired care for stroke survivors and partners/carers throughout—and 
beyond—trial participation. Recruiter education training programmes 
should also ensure recruiters and health- care professionals are alert to 
the individual information needs and support requirements of stroke 
survivors and partners/carers.
6  | STRENGTHS AND LIMITATIONS
The use of Conversation Café created a relaxed, informal yet sup-
portive environment to encourage discussion around this topic, cre-
ating rich data with the added bonus participants enjoyed the event. 
Some stroke survivors experienced moderate- to- severe aphasia, mak-
ing prolonged speech tiring and full- participation difficult. However, 
group organizers advised that the Café topic had generated such a high 
level of interest that some group members experiencing moderate- to- 
severe aphasia had spoken in public for the first time at this event.
Retrospectively, many participants revealed suggested cognitive 
and functional difficulties that could affect informed decision making. 
Nevertheless, retrospective questions concerning motivational, attitu-
dinal, cognitive or affective states may also be affected by recall bias. 
Further, participants were not reflecting on actual trial participation. 
Therefore, views and motivations within a real setting are unknown.
Participants are not fully representative of the stroke survivor com-
munity. For example, Group A advised that while group numbers had 
significantly increased for the Conversation Café event, some people 
had advised they had chosen not to attend because they disagreed 
with research involving stem cells.
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